Background: Trilostane is the drug of choice to treat pituitary-dependent hyperadrenocorticism (PDH) in dogs, but there is still controversy about which protocol best controls the clinical signs and results of adrenal functioning test.
Objectives: To compare the efficacy of twice daily (BID) versus once daily (SID) trilostane administration and to compare the safety of both protocols in the treatment of dogs with PDH.
Animals: Thirty-two client-owned dogs diagnosed with PDH between 2008 and 2010 and treated with trilostane either BID or SID.
Methods: In this prospective randomized study, 2 trilostane protocols were evaluated on the basis of the owner's perception of clinical signs, on the results of laboratory tests, and on the results of the ACTH stimulation test in dogs with PDH. Dogs were followed up for a period of 1 year.
Results: During the study, more dogs in the BID group had complete clinical recovery than in the SID group. However, there was no significant difference in the mean post-ACTH cortisol concentration between groups. Basal cortisol concentration at 6 months was higher in animals treated SID compared with animals treated BID. Mean total daily doses of trilostane used to control PDH, as well as adverse effects observed in the course of the study, in both groups were not statistically different.
Conclusion And Clinical Importance: Adverse effects were mild using either protocol of treatment. Using trilostane BID might increase the number of dogs with a good clinical response compared with using trilostane SID.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jvim.12207 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Skin fragility in a cat presenting with pituitary-dependent hyperadrenocorticism.
JFMS Open Rep
June 2023
Langford Small Animal Referral Hospital, Langford, Bristol, UK.
Case Summary: A case of skin fragility in an 8-year-old domestic shorthair cat with pituitary-dependent hyperadrenocorticism is described. The cat was referred to the Feline Centre at Langford Small Animal Hospital with a 2-month history of multiple skin wounds with no known traumatic aetiology. A low-dose dexamethasone suppression test was performed before referral, which was consistent with hyperadrenocorticism.
View Article and Find Full Text PDFSurvival of dogs with pituitary-dependent hyperadrenocorticism treated twice daily with low doses of trilostane.
Vet Rec
August 2022
Department of Small Animal Medicine and Surgery, Veterinary School, Complutense University of Madrid, Madrid, Spain.
Background: Twice daily low trilostane doses have proven to be effective to manage canine Cushing's syndrome. However, survival and prognostic factors in dogs treated with this protocol have not been evaluated. The aim of the study was to evaluate survival and prognostic factors, including systolic blood pressure (SBP) at diagnosis, in dogs with pituitary-dependent hypercortisolism (PDH) treated with low trilostane doses.
View Article and Find Full Text PDFFeline comorbidities: Recognition, diagnosis and management of the cushingoid diabetic.
J Feline Med Surg
January 2021
DVM, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA.
Practical Relevance: Diabetes mellitus (DM) is a common feline endocrinopathy, and is often driven by underlying insulin resistance with associated pancreatic beta (β)-cell dysfunction. Although spontaneous hyperadrenocorticism (HAC) with hypercortisolemia (hypercortisolism) is relatively uncommon in cats, it is a well-established cause of insulin resistance and is routinely associated with DM in this species.
Clinical Challenges: Many of the clinical signs associated with feline HAC are subtle and may be attributed to concurrent DM or the aging process.
Inhibition of 3β-Hydroxysteroid Dehydrogenase Type 1 Suppresses Interleukin-6 in Breast Cancer.
J Surg Res
September 2019
Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei, Taiwan; Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan; Mackay Junior College of Medicine, Nursing, and Management, Taipei, Taiwan. Electronic address:
Background: Recently, we demonstrated that the expression of 3β-hydroxysteroid dehydrogenase type 1 (HSD3B1) in breast cancer is associated with shorter recurrence-free survival, and genetic or pharmacologic inhibition of HSD3B1 reduced colony formation and xenograft growth. However, the mechanisms are unclear.
Methods: Triple-negative MDA-MB-231 and BT-20 breast cancer cells underwent HSD3B1 silencing.
Diabetes mellitus remission in a cat with pituitary-dependent hyperadrenocorticism after trilostane treatment.
JFMS Open Rep
April 2018
Diabetic Remission Clinic, Department of Clinical Science and Services, Royal Veterinary College, University of London, North Mimms, UK.
Case Summary: An 8-year-old male neutered Persian cat was presented with polyuria, polydipsia, polyphagia and muscle weakness associated with a 7 month history of diabetes mellitus (DM). The cat had initially been treated with neutral protamine Hagedorn (NPH) insulin 2 U q12h, followed by porcine lente insulin 2 U q12h and, most recently, 3 U glargine insulin q12h, without improvement of clinical signs. The cat also suffered from concurrent symmetrical bilateral alopecia of thorax and forelimbs, abdominal distension and lethargy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!